Skip to content

The Effect of the Art-based Mandala Intervention on the Quality of Life of Cancer Patients Receiving Chemotherapy

The Effect of the Art-based Mandala Intervention on the Quality of Life of Cancer Patients Receiving Chemotherapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05344820
Acronym
ARQULA
Enrollment
90
Registered
2022-04-25
Start date
2022-05-19
Completion date
2022-12-31
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alexithymia, Cancer, Chemotherapy Effect, Fatigue, Quality of Life, Rumination

Keywords

cancer, Chemotherapy Effect, Fatigue, Quality of Life, Rumination, Alexithymia

Brief summary

The aim of this study is to determine the effect of mandala application on fatigue, quality of life, rumination and alexithymia in cancer patients receiving chemotherapy.

Detailed description

A randomized controlled study on the effect of mandala application on cancer related fatigue, quality of life, rumination and alexithymia in cancer patients receiving chemotherapy has not been found in the literature. The aim of this study is to determine the effect of mandala application on fatigue, quality of life, rumination and alexithymia in cancer patients receiving chemotherapy.

Interventions

BEHAVIORALArt based mandala

To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.

Sponsors

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Conscious and no communication problems * Being literate * Having a cancer diagnosis * Receiving chemotherapy treatment (planned to continue treatment for 8 more weeks) * Willing to participate in our study voluntarily

Exclusion criteria

* Not being willing to participate in the research * Desire to leave the study at any time * Deterioration of compliance with the working criteria during the time of the study, * Those who do not participate in up to four mandala applications during the study period * Those who cannot use a pen * Those with a diagnosis of psychiatric and neurological disease * Patients who are scheduled for drug intervention, radiotherapy, surgery other than chemotherapy within 8 weeks

Design outcomes

Primary

MeasureTime frameDescription
level of quality of life1 weekLevel of quality of life as assessed by the Quality of Life Scale for the Treatment and Research of Cancer (min:0, max:100,with higher values indicating a higher functioning in functional scales and an increased presence of symptoms in symptom scales)
level of fatigue1 weeklevel of fatigue assessed by the Piper Fatigue Scale (min:0, max, 100, higher values means higher fatigue)

Secondary

MeasureTime frameDescription
level of alexithymia1 weeklevel of alexithymia assessed by Toronto Alexythimia Scale (higher values means more alexithymic)
level of rumination1 weeklevel of rumination assessed by ruminative thought scale (higher values means more ruminative thought)

Countries

Turkey (Türkiye)

Contacts

Primary ContactElif Yıldırım Ayaz, M.D.
drelifyildirim@hotmail.com+905325148300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026